CD86 and CD80 Differentially Modulate the Suppressive Function of Human Regulatory T Cells

Journal of Immunology

Volumn 172, Issue 5, 2004, Pages 2778-2784

  Zheng, Yong ^a   Manzotti, Claire N ^a   Liu, Michael ^a   Burke, Fiona ^a   Mead, Karen I ^a   Sansom, David M ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALLOANTIGEN; ANTIBODY; B7 ANTIGEN; CD28 ANTIGEN; CD80 ANTIBODY; CD86 ANTIBODY; CD86 ANTIGEN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; UNCLASSIFIED DRUG;

ANTIGEN BINDING; ANTIGEN EXPRESSION; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE COURSE; HUMAN; HUMAN CELL; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOMODULATION; IMMUNOREGULATION; IN VIVO STUDY; LIGAND BINDING; PRIORITY JOURNAL; PROTEIN FUNCTION; T LYMPHOCYTE;

EID: 1342345915     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.172.5.2778     Document Type: Article

References (46)

1. Sansom, D. M., C. N. Manzotti, and Y. Zheng. 2003. What's the difference between CD80 and CD86? Trends Immunol. 24:313.
2. Salomon, B., and J. A. Bluestone. 2001. Complexities of CD28/B7: CTLA-4 costimulatory pathways in autoimmunity and transplantation. Annu. Rev. Immunol. 19:225.
3. Sansom, D. M. 2000. CD28, CTLA-4 and their ligands: who does what and to whom? Immunology 101:169.
4. Sharpe, A., and G. J. Freeman. 2002. The B7-CD28 superfamily. Nat. Rev. Immunol. 2:116.
5. Waterhouse, P., J. M. Penninger, E. Timms, A. Wakeham, A. Shahinian, K. P. Lee, C. B. Thompson, H. Griesser, and T. W. Mak. 1995. Lymphoproliferative disorders with early lethality in mice deficient in CTLA-4. Science 270:985.
6. Inaba, K., M. Inaba, M. Witmer-Pack, K. Hatchcock, R. Hodes, and R. M. Steinman. 1995. Expression of B7 costimulator molecules on mouse dendritic cells. Adv. Exp. Med. Biol. 378:65.
7. Inaba, K., M. Witmer-Pack, M. Inaba, K. S. Hathcock, H. Sakuta, M. Azuma, H. Yagita, K. Okumura, P. S. Linsley, S. Ikehara, et al. 1994. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180:1849.
8. Azuma, M., D. Ito, H. Yagita, K. Okumura, J. Phillips, L. Lanier, and C. Somoza. 1993. B70 antigen is a second ligand for CTLA-4 and CD28. Nature. 366:76.
9. Freeman, G. J., G. S. Gray, C. D. Gimmi, D. B. Lombard, L. Zhou, M. White, J. D. Fingeroth, J. B. Gribben, and L. M. Nadler. 1991. Structure, expression, and T cell costimulatory activity of the murine homologue of the human B lymphocyte activation antigen B7. J. Exp. Med. 174:625.
10. Freeman, G. J., J. G. Gribben, V. A. Boussiotis, J. W. Ng, V. A. Restivo, L. A. Lombard, G. S. Gray, and L. M. Nadler. 1993. Cloning of B7-2: a CTLA-4 counter-receptor that costimulates human T cell proliferation. Science 262:909.
11. Sharpe, A. H. 1995. Analysis of lymphocyte costimulation in-vivo using transgenic and knockout mice. Curr. Opin. Immunol. 7:389.
12. Borriello, F., M. P. Sethna, S. D. Boyd, A. N. Schweitzer, E. A. Tivol, D. Jacoby, T. B. Strom, E. M. Simpson, G. J. Freeman, and A. H. Sharpe. 1997. B7-1 and B7-2 have overlapping, critical roles in immunoglobulin class switching and germinal center formation. Immunity 6:303.
13. + regulatory cells that control intestinal inflammation. J. Exp. Med. 192:295.
14. + regulatory T cells constitutively expressing cytotoxic T lymphocyte-associated antigen 4. J. Exp. Med. 192:303.
15. + regulatory T cells. Eur. J. Immunol. 32:2888.
16. + immunoregulatory T cells that control autoimmune diabetes. Immunity 12:431.
17. Sakaguchi, S. 2000. Animal models of autoimmunity and their relevance to human diseases. Curr. Opin. Immunol. 12:684.
18. + regulatory T cells prevent graft rejection: CTLA-4- and IL-10-dependent immunoregulation of alloresponses. J. Immunol. 168:1080.
19. + immune regulatory cells are required for induction of tolerance to alloantigen via costimulatory blockade. J. Exp. Med. 193:1311.
20. + T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J. Exp. Med. 192:1213.
21. Dhodapkar, M. V., R. M. Steinman, J. Krasovsky, C. Munz, and N. Bhardwaj. 2001. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193:233.
22. Steinman, R. M., and M. C. Nussenzweig. 2002. Inaugural Article: Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. USA 99:351.
23. + regulatory T cells by antigen-processing dendritic cells. J. Exp. Med. 198:235.
24. + regulatory T cells in vivo. J. Exp. Med. 198:249.
25. Janeway, C. A., Jr., and R. Medzhitov. 2002. Innate immune recognition. Annu. Rev. Immunol. 20:197.
26. Medzhitov, R., and C. Janeway, Jr. 2000. The Toll receptor family and microbial recognition. Trends Microbiol. 8:452.
27. + T cell-mediated suppression by dendritic cells. Science 299:1033.
28. Lanier, L., S. O'Fallon, C. Somoza, J. H. Phillips, P. S. Linsley, K. Okumura, D. Ito, and M. Azuma. 1995. CD80(B7) and CD86(B70) provide similar costimulatory signals for T cell proliferation, cytokine production and generation of CTL. J. Immunol. 154:97.
29. Yamada, A., K. Kishimoto, V. M. Dong, M. Sho, A. D. Salama, N. G. Anosova, G. Benichou, D. A. Mandelbrot, A. H. Sharpe, L. A. Turka, et al. 2001. CD28-independent costimulation of T cells in alloimmune responses. J. Immunol. 167:140.
30. Judge, T. A., Z. Wu, X. G. Zheng, A. H. Sharpe, M. H. Sayegh, and L. A. Turka. 1999. The role of CD80, CD86, and CTLA4 in alloimmune responses and the induction of long-term allograft survival. J. Immunol. 162:1947.
31. Lenschow, D. J., S. C. Ho, H. Sattar, L. Rhee, G. Gray, N. Nabavi, K. C. Herold, and J. A. Bluestone. 1995. Differential effects of anti-B7-1 and B7-2 monoclonal antibody treatment on the development of diabetes in the nonobese diabetic mouse. J. Exp. Med. 181:1145.
32. +, murine myelogenous leukemia. Blood 99:2146.
33. + naturally anergic and suppressive T cells: induction of autoimmune disease by breaking their anergic/suppressive state. Int. Immunol. 10:1969.
34. Collins, A., D. Brodie, R. Gilbert, A. Iaboni, R. Manso-Sancho, B. Walse, D. Stuart, P. van der Merwe, and S. Davis. 2002. The interaction properties of costimulatory molecules revisited. Immunity 17:201.
35. + T regulatory cells suppress naive and memory t cell proliferation and can be expanded in vitro without loss of function. J. Exp. Med. 193:1295.
36. + suppressor T cells: more questions than answers. Nat. Rev. Immunol. 2:389.
37. Egen, J., and J. Allison. 2002. Cytotoxic T lymphocyte antigen-4 accumulation in the immunological synapse is regulated by TCR signal strength. Immunity 16:23.
38. Lenschow, D., Y. Zeng, J. Thistlethwaite, A. Monty, W. Brady, N. Gibson, P. Linsley, and J. Bluestone. 1992. Longterm survival of xenogeneic pancreatic islet grafts induced by CTLA4Ig. Science 257:789.
39. Linsley, P. S., P. M. Wallace, J. Johnson, M. G. Gibson, J. L. Greene, J. A. Ledbetter, C. Singh, and M. A. Tepper. 1992. Immunosuppression in vivo by a soluble form of the CTLA-4 T cell activation molecule. Science 257:792.
40. Larsen, C. P., E. T. Elwood, D. Z. Alexander, S. C. Ritchie, R. Hendrix, C. Tucker-Burden, H. R. Cho, A. Aruffo, D. Hollenbaugh, P. S. Linsley, et al. 1996. Long-term acceptance of skin and cardiac allografts after blocking CD40 and CD28 pathways. Nature 381:434.
41. Guinan, E. C., V. A. Boussiotis, D. Neuberg, L. L. Brennan, N. Hirano, L. M. Nadler, and J. G. Gribben. 1999. Transplantation of anergic histoincompatible bone marrow allografts. N. Engl. J. Med. 340:1704.
42. Abrams, J. R., M. G. Lebwohl, C. A. Guzzo, B. V. Jegasothy, M. T. Goldfarb, B. S. Goffe, A. Menter, N. J. Lowe, G. Krueger, M. J. Brown, et al. 1999. CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris. J. Clin. Invest. 103:1243.
43. + regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194:823.
44. Hodi, F. S., M. C. Mihm, R. J. Soiffer, F. G. Haluska, M. Butler, M. V. Seiden, T. Davis, R. Henry-Spires, S. MacRae, A. Willman, et al. 2003. Biologic activity of cytotoxic T lymphocyte-associated antigen 4 antibody blockade in previously vaccinated metastatic melanoma and ovarian carcinoma patients. Proc. Natl. Acad. Sci. USA 100:4712.
45. Phan, G. Q., J. C. Yang, R. M. Sherry, P. Hwu, S. L. Topalian, D. J. Schwartzentruber, N. P. Restifo, L. R. Haworth, C. A. Seipp, L. J. Freezer, et al. 2003. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA
46. Leach, D. R., M. F. Krummel, and J. P. Allison. 1996. Enhancement of antitumour immunity by CTLA-4 blockade. Science 271:1734.